The Trump administration announced a set of price-lowering agreements on Thursday with two of the world’s leading pharmaceutical companies, Novo Nordisk and Eli Lilly. The deals target GLP-1 receptor agonists—drugs widely prescribed for weight management and diabetes—that have faced scrutiny for their rising costs in recent years. By negotiating rebates and price caps, officials say…